Logo image of OSTX

OS THERAPIES INC (OSTX) Stock Fundamental Analysis

NYSEARCA:OSTX - NYSE Arca - US68764Y2072 - Common Stock - Currency: USD

1.8  -0.04 (-2.17%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OSTX. OSTX was compared to 559 industry peers in the Biotechnology industry. OSTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OSTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OSTX has reported negative net income.
In the past year OSTX has reported a negative cash flow from operations.
OSTX Yearly Net Income VS EBIT VS OCF VS FCFOSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -312.31%, OSTX is not doing good in the industry: 93.56% of the companies in the same industry are doing better.
OSTX has a worse Return On Equity (-2162.75%) than 83.54% of its industry peers.
Industry RankSector Rank
ROA -312.31%
ROE -2162.75%
ROIC N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSTX Yearly ROA, ROE, ROICOSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OSTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSTX Yearly Profit, Operating, Gross MarginsOSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for OSTX has been increased compared to 1 year ago.
There is no outstanding debt for OSTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OSTX Yearly Shares OutstandingOSTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
OSTX Yearly Total Debt VS Total AssetsOSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M

2.2 Solvency

Based on the Altman-Z score of -13.93, we must say that OSTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OSTX (-13.93) is worse than 78.89% of its industry peers.
OSTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.93
ROIC/WACCN/A
WACCN/A
OSTX Yearly LT Debt VS Equity VS FCFOSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

OSTX has a Current Ratio of 1.16. This is a normal value and indicates that OSTX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of OSTX (1.16) is worse than 85.87% of its industry peers.
OSTX has a Quick Ratio of 1.16. This is a normal value and indicates that OSTX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.16, OSTX is doing worse than 85.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
OSTX Yearly Current Assets VS Current LiabilitesOSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

OSTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -128.56%.
EPS 1Y (TTM)-128.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-152.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OSTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.40% yearly.
OSTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 464.63% yearly.
EPS Next Y163.44%
EPS Next 2Y40.09%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue Next Year26664%
Revenue Next 2Y1030.05%
Revenue Next 3Y464.63%
Revenue Next 5YN/A

3.3 Evolution

OSTX Yearly Revenue VS EstimatesOSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 10M 20M 30M
OSTX Yearly EPS VS EstimatesOSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OSTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSTX Price Earnings VS Forward Price EarningsOSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSTX Per share dataOSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

OSTX's earnings are expected to grow with 24.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.09%
EPS Next 3Y24.4%

More info and screens

0

5. Dividend

5.1 Amount

OSTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OS THERAPIES INC

NYSEARCA:OSTX (6/13/2025, 11:58:34 AM)

1.8

-0.04 (-2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners0.77%
Inst Owner Change168.47%
Ins Owners20.37%
Ins Owner Change7.85%
Market Cap50.58M
Analysts82
Price Target13.77 (665%)
Short Float %1.39%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-129.14%
Min EPS beat(2)-194.12%
Max EPS beat(2)-64.16%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-7.95%
EPS NQ rev (1m)-18.19%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 82.43
P/tB 82.43
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -312.31%
ROE -2162.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z -13.93
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-128.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-152.07%
EPS Next Y163.44%
EPS Next 2Y40.09%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year26664%
Revenue Next 2Y1030.05%
Revenue Next 3Y464.63%
Revenue Next 5YN/A
EBIT growth 1Y-56.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-142.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.18%
OCF growth 3YN/A
OCF growth 5YN/A